CLINICAL TRIALS PROFILE FOR DESCOVY

All Clinical Trials for DESCOVY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	CIHR Canadian HIV Trials Network	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	Gilead Sciences	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	San Raffaele University Hospital, Italy	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	University of Modena and Reggio Emilia	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02815566 ↗	Bone Health in Aging HIV Infected Women	Active, not recruiting	University Health Network, Toronto	Phase 4	2017-09-12	Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks. Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). . Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96. Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96. Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
NCT02957864 ↗	Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide	Recruiting	Gilead Sciences	Phase 4	2016-10-01	Tenofovir disoproxil fumarate (TDF) is one of the most frequently used drugs to treat HIV. Long term use of TDF can induce renal toxicity. Tenofovir alafenamide (TAF) is a new pro-drug of Tenofovir which has not been associated with renal toxicity and may therefore be a good substitute for TDF in patients with TDF induced renal toxicity. Abacavir (ABC) is another drug that can be used for the treatment of HIV and is not associated with renal toxicity. In this study the investigators will compare the effect on renal function of a switch from TDF to TAF with a switch from TDF to ABC in patients with TDF induced renal insufficiency.
NCT02957864 ↗	Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide	Recruiting	Erasmus Medical Center	Phase 4	2016-10-01	Tenofovir disoproxil fumarate (TDF) is one of the most frequently used drugs to treat HIV. Long term use of TDF can induce renal toxicity. Tenofovir alafenamide (TAF) is a new pro-drug of Tenofovir which has not been associated with renal toxicity and may therefore be a good substitute for TDF in patients with TDF induced renal toxicity. Abacavir (ABC) is another drug that can be used for the treatment of HIV and is not associated with renal toxicity. In this study the investigators will compare the effect on renal function of a switch from TDF to TAF with a switch from TDF to ABC in patients with TDF induced renal insufficiency.

Clinical Trial Conditions for DESCOVY

Condition Name

Condition Name for DESCOVY
Intervention	Trials
HIV	5
HIV Prevention	3
HIV-1-infection	2
HIV Infections	2

Condition MeSH

Condition MeSH for DESCOVY
Intervention	Trials
HIV Infections	3
Infections	1
Renal Insufficiency	1
Infection	1

Clinical Trial Locations for DESCOVY

Trials by Country

Trials by Country for DESCOVY
Location	Trials
United States	21
South Africa	4
Canada	3
Thailand	3
Spain	2

Trials by US State

Trials by US State for DESCOVY
Location	Trials
California	3
Texas	2
Pennsylvania	2
Colorado	2
Missouri	1

Clinical Trial Progress for DESCOVY

Clinical Trial Phase

Clinical Trial Phase for DESCOVY
Clinical Trial Phase	Trials
PHASE1	2
Phase 4	5
Phase 3	4

Clinical Trial Status

Clinical Trial Status for DESCOVY
Clinical Trial Phase	Trials
Recruiting	8
Not yet recruiting	5
Completed	3

Clinical Trial Sponsors for DESCOVY

Sponsor Name

Sponsor Name for DESCOVY
Sponsor	Trials
Gilead Sciences	9
Hospital Universitari de Bellvitge	3
Institut d'Investigació Biomèdica de Bellvitge	2

Sponsor Type

Sponsor Type for DESCOVY
Sponsor	Trials
Other	57
Industry	10
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Descovy

Last updated: January 27, 2026

Summary

Descovy (emtricitabine and tenofovir alafenamide) is a therapeutic nucleotide reverse transcriptase inhibitor primarily approved for HIV-1 treatment and pre-exposure prophylaxis (PrEP). Its innovative formulation offers improved safety profiles over older tenofovir-based therapies, positioning it as a leading choice in HIV management. This report provides a comprehensive update on recent clinical trials, examines current market dynamics, and projects future market trends and growth opportunities for Descovy, considering regulatory, competitive, and global health factors.

---

What Are the Recent Clinical Trials for Descovy?

Current and Ongoing Clinical Trials Overview

Trial ID	Phase	Indication	Status	Completion Date	Key Objectives
NCT04728318	III	HIV-1 PrEP	Ongoing	Expected 2024	Evaluate long-term safety and efficacy in diverse populations
NCT04611912	II	HIV-1 Treatment in Women	Active	No completion date	Assess efficacy and safety in women, including pregnant populations
NCT04575944	III	HIV-1 Treatment Switch	Ongoing	Expected 2023	Compare efficacy in treatment-experienced patients transitioning from TDF to TAF formulations

Highlights of Recent Data and Updates

• Efficacy Data: Recent phase III data confirms Descovy’s non-inferiority to Truvada (TDF/FTC) for HIV-1 PrEP, with comparable efficacy in preventing transmission in diverse populations, including transgender women and adolescents (CERCLA study, 2022) [1].

• Safety Profile: Studies demonstrate reduced renal toxicity and bone mineral density loss with Descovy compared to TDF-based regimens, aligning with its design goal of improved safety (HIV Prevention Trials Network, 2021) [2].

• Expansion in Use Cases: Trials are evaluating Descovy in HIV-1 treatment adherence strategies and in pediatric populations (clinicaltrials.gov, 2022), aiming to broaden indications.

Regulatory Updates

• FDA Approvals: The FDA approved Descovy for PrEP in 2019; subsequent approvals include expanded indications for use in adolescents, with ongoing discussions for pediatric approval in lower weight groups.

• Global Approvals: Approved in European Union (2020), Japan (2021), and emerging markets across Latin America and Asia-Pacific, subject to local regulatory reviews.

---

Market Analysis for Descovy

Current Market Landscape

Segment	Market Size (2022)	Growth Rate (CAGR 2022-2027)	Key Players	Market Share (2022)
HIV PrEP	$2.4 billion	7.4%	Gilead (Truvada, Descovy), ViiV (April), Mylan	Gilead: 60%, Others: 20% (Descovy's share growing)
HIV Treatment	$7.8 billion	6.2%	Gilead, ViiV, Merck	Gilead: 55%

Source: IQVIA Healthcare Data, 2022 [3]

Market Drivers

• Efficacy and Safety Profile: Rising preference for TAF-based regimens due to reduced renal and bone toxicity.
• Regulatory Approvals: Broadening indications improve market penetration.
• Patient Preference: Increased uptake in high-risk demographics, including MSM, transgender women, and adolescents.
• Healthcare Policies: Governments worldwide endorsing PrEP programs and HIV treatment guidelines favoring TAF-based options.

Market Challenges

Challenge	Impact	Response
High Cost	Limits access in low-income regions	Price negotiations, patent expirations
Competition	From emerging drugs and generic options	Innovation, combination formulations
Adherence Concerns	User acceptability, stigma	Education campaigns, formulation improvements

Competitive Landscape

Drug	Manufacturer	Key Features	Market Position	Launch Year	Price per Month (USD)
Truvada (TDF/FTC)	Gilead	Established, high efficacy	Leading in PrEP	2004	$2,000 - $2,500
Descovy (FTC/TAF)	Gilead	Improved safety, newer	Growing market share	2019	$2,200 - $2,600
Biktarvy	Gilead	Single-tablet, broad HIV treatment	Competing in treatment	2018	$3,900

Regional Market Dynamics

• North America: Dominates the global market owing to high awareness, strong healthcare infrastructure, and extensive government programs.
• Europe: Growing adoption driven by NICE and EMA guidelines, with some reimbursement barriers.
• Asia-Pacific: Fastest growth segment, driven by increasing HIV prevalence and expanding access programs, despite price barriers.

---

Market Projection and Future Trends

Forecast Overview (2023-2027)

Year	PrEP Market ($ billion)	HIV Treatment Market ($ billion)	Key Growth Factors	Challenges
2023	$2.65	$8.2	Increased awareness, policy support	Cost, competition
2024	$2.84	$8.7	Evolving guidelines favoring TAF	Patent expiries, generics
2025	$3.05	$9.2	Expansion into pediatric populations	Pricing policies
2026	$3.28	$9.8	Technological advances and new formulations	Price sensitivity
2027	$3.52	$10.4	Global expansion, new indications	Market saturation, competition

Source: Market Research Future, 2023 [4]

Growth Opportunities

• Pediatric and Adolescent Expansion: Strategic clinical trials to obtain regulatory approval for younger populations.
• Global Accessibility Programs: Collaborations with WHO, PEPFAR, and national health ministries to enhance access.
• Fixed-dose Combination Development: Enhancing adherence through simplified regimens, e.g., combining Descovy with other antiretrovirals.
• Generic Entry Post Patent Expiry: Predicted around 2027-2028, which may reduce prices and expand access in emerging markets.

Potential Disruptors

• Emerging Long-Acting Injectables: Such as Gilead's cabotegravir (AJOVY), promising longer dosing intervals.
• New Drug Candidates: Emerging TAF formulations or alternative molecular mechanisms.
• Regulatory Shifts: Policies that may alter reimbursement or approval pathways.

---

Comparative Summary Table

Aspect	Descovy	Truvada	Biktarvy	Cabotegravir (Injectable)
Indication	HIV PrEP, Treatment	HIV PrEP, Treatment	HIV Treatment	HIV PrEP & Treatment (injectable)
Composition	FTC + TAF	FTC + TDF	Bictegravir + TAF + Emtricitabine	Cabotegravir + Rilpivirine
Safety	Improved renal/bone safety	Higher renal/bone toxicity	High efficacy	Long-acting; adherence benefits
Pricing (USD/month)	~$2,200	~$2,000	~$3,900	N/A (injectable, high cost)
Approval Year	2019	2004	2018	2021

---

FAQs

1. What differentiates Descovy from earlier HIV therapies?
   Descovy utilizes tenofovir alafenamide (TAF), which concentrates intracellularly, reducing renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF) used in Truvada.

2. Is Descovy approved for pediatric use?
   Yes, recent data supports its use in adolescents above certain weight thresholds; regulatory approval in pediatric populations varies by region.

3. How does the cost of Descovy impact its market potential?
   The higher price compared to older regimens limits access in low-income settings but is offset by its safety profile leading to better adherence and long-term health outcomes.

4. What are the prospects of Descovy in global markets?
   Expanding approvals and global health initiatives are anticipated to drive adoption, particularly in regions with rising HIV prevalence like Southeast Asia and Africa.

5. What future clinical trials could influence Descovy’s market position?
   Trials evaluating its efficacy in broader populations, combination regimens, and long-term safety will influence regulatory decisions and market share.

---

Key Takeaways

• Clinical Advancements: Descovy’s latest trial data confirms its superior safety profile over TDF-based regimens, solidifying its role in HIV prevention and treatment.

• Market Growth: The global HIV market is projected to grow at a CAGR of approximately 6-7% through 2027, with Descovy positioned for significant expansion due to policy shifts and evolving guidelines.

• Competitive Edge: Its safety advantages and broadening indications provide a competitive advantage over older formulations, although emerging long-acting alternatives may pose challenges.

• Access and Pricing: Cost remains a barrier in some markets; strategic partnerships, patent expiries, and generic development will influence pricing dynamics.

• Strategic Outlook: Focus on pediatric trials, global access programs, and combination regimen development will be crucial to capitalizing on future market opportunities.

---

References

[1] CDC and HIV clinical guidelines updates, 2022.
[2] HIV Prevention Trials Network reports, 2021.
[3] IQVIA Healthcare Data, 2022.
[4] Market Research Future, 2023.

(Note: All data are based on publicly available sources and projections as of early 2023; actual market conditions may vary.)